{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:28:45Z","timestamp":1775485725025,"version":"3.50.1"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118657","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:53:26Z","timestamp":1770479606000},"page":"118657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in pyrimidine-like heterocyclic scaffolds: Innovative synthetic method for malic enzyme inhibition in pancreatic ductal adenocarcinoma (PDAC) - A comprehensive review"],"prefix":"10.1016","volume":"307","author":[{"given":"Shubham","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2026.118657_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11224-021-01871-2","article-title":"In silico docking and ADME study of deketene curcumin derivatives (DKC) as an aromatase inhibitor or antagonist to the estrogen-alpha positive receptor (Er\u03b1+): potent application of breast cancer","volume":"33","author":"Shah","year":"2022","journal-title":"Struct. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118657_bib3","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.31557\/APJCP.2021.22.8.2587","article-title":"Anticancer potential of silibinin loaded polymeric nanoparticles against breast cancer cells: insight into the apoptotic genes targets","volume":"22","author":"Pourgholi","year":"2021","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"Sep","key":"10.1016\/j.ejmech.2026.118657_bib4","article-title":"Innovative approaches for cancer treatment: current perspectives and new challenges","volume":"13","author":"Pucci","year":"2019","journal-title":"ecancermedicalscience"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118657_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11051-024-06000-8","article-title":"A holistic review of recent advances in nano-based drug delivery systems for the treatment of triple-negative breast cancer (TNBC)","volume":"26","author":"Mehta","year":"2024","journal-title":"J. Nanoparticle Res."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118657_bib6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/cancers11081125","article-title":"Novel strategies for cancer treatment: highlights from the 55th IACR annual conference","volume":"11","author":"Charmsaz","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.118657_bib7","article-title":"Design and fabrication of a dual-drug loaded nano-platform for synergistic anticancer and cytotoxicity effects on the expression of leptin in lung cancer treatment","volume":"73","author":"Alagheband","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118657_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1515\/jbcpp-2020-0262","article-title":"In silico approach: docking study of oxindole derivatives against the main protease of COVID-19 and its comparison with existing therapeutic agents","volume":"32","author":"Shah","year":"2021","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118657_bib9","series-title":"Molecular Pathogenesis of Pancreatic Cancer","first-page":"241","author":"Grant","year":"2016"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118657_bib10","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-16-2319","article-title":"Current and emerging therapies in metastatic pancreatic cancer","volume":"23","author":"Manji","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib11","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy","volume":"12","author":"Sarantis","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/acsmedchemlett.2c00369","article-title":"In the quest for potent and selective malic enzyme 3 inhibitors for the treatment of pancreatic ductal adenocarcinoma","volume":"14","author":"Sheth","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118657_bib13","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1101\/gad.1158703","article-title":"Activated Kras and Ink4a\/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma","volume":"17","author":"Aguirre","year":"2003","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/jomfp.JOMFP_60_17","article-title":"Alteration of cellular metabolism in cancer cells and its therapeutic prospects","volume":"21","author":"Biswal","year":"2017","journal-title":"J. Oral Maxillofac. Pathol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118657_bib15","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0300-9084(92)90016-8","article-title":"Deviant energetic metabolism of glycolytic cancer cells","volume":"74","author":"Baggetto","year":"1992","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118657_bib16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/jid.2014.385","article-title":"Human mitochondrial NAD(P)+\u2013Dependent malic enzyme participates in cutaneous melanoma progression and invasion","volume":"135","author":"Chang","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118657_bib17","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/cas.13594","article-title":"Expression of cytosolic malic enzyme (<scp>ME<\/scp> 1) is associated with disease progression in human oral squamous cell carcinoma","volume":"109","author":"Nakashima","year":"2018","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118657_bib20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s10555-021-10006-2","article-title":"The role of metabolic ecosystem in cancer progression \u2014 metabolic plasticity and mTOR hyperactivity in tumor tissues","volume":"40","author":"Sebesty\u00e9n","year":"2021","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-024-00482-x","article-title":"Cancer metabolism and carcinogenesis","volume":"13","author":"Yang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118657_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.944","article-title":"Untargeted metabolomics identifies the potential role of monocarboxylate transporter 6 (MCT6\/SLC16A5) in lipid and amino acid metabolism pathways","volume":"10","author":"Ren","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118657_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.yexcr.2011.11.014","article-title":"Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment","volume":"318","author":"Rattigan","year":"2012","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-020-01629-4","article-title":"Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma","volume":"39","author":"Feng","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35106-y","article-title":"ME1 promotes basal-like breast cancer progression and associates with poor prognosis","volume":"8","author":"Liao","year":"2018","journal-title":"Sci. Rep."},{"issue":"Mar","key":"10.1016\/j.ejmech.2026.118657_bib25","article-title":"Hexosamine biosynthetic pathway and glycosylation regulate cell migration in Melanoma cells","volume":"9","author":"de Queiroz","year":"2019","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118657_bib26","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/cas.14105","article-title":"Roles of the hexosamine biosynthetic pathway and pentose phosphate pathway in bile acid\u2010induced cancer development","volume":"110","author":"Munemoto","year":"2019","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118657_bib27","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","article-title":"Oxidative phosphorylation as an emerging target in cancer therapy","volume":"24","author":"Ashton","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib28","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1038\/s41598-017-02997-2","article-title":"Global temporal patterns of pancreatic cancer and association with socioeconomic development","volume":"7","author":"Wong","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118657_bib30","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118657_bib31","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jso.24317","article-title":"Combination gemcitabine\/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: results of a Phase II prospective trial","volume":"114","author":"Postlewait","year":"2016","journal-title":"J. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118657_bib32","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1159\/000201503","article-title":"ESPAC-1 trial progress report: the European randomized adjuvant Study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer","volume":"58","author":"Neoptolemos","year":"1997","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with Gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer","volume":"268","author":"Jang","year":"2018","journal-title":"Ann. Surg."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118657_bib34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/JCO.2016.68.5081","article-title":"Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity Score matched analysis","volume":"35","author":"Mokdad","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118657_bib35","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/cncr.25763","article-title":"Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma","volume":"117","author":"Artinyan","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10434-001-0123-4","article-title":"Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration","volume":"8","author":"Breslin","year":"2001","journal-title":"Ann. Surg Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118657_bib37","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118657_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol."},{"issue":"34","key":"10.1016\/j.ejmech.2026.118657_bib39","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: a phase III Study of active maintenance olaparib versus placebo for germline BRCA-Mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118657_bib40","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ejmech.2026.118657_bib41","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118657_bib42","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"10409","key":"10.1016\/j.ejmech.2026.118657_bib43","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118657_bib44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA -Mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"Jul","key":"10.1016\/j.ejmech.2026.118657_bib45","article-title":"Unraveling the gut microbiome's contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives","volume":"15","author":"Tabrizi","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118657_bib46","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s002689900604","article-title":"Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastasis","volume":"23","author":"Beger","year":"1999","journal-title":"World J. Surg."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118657_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e12392","article-title":"Integrative structural and functional analysis of human malic enzyme 3: a potential therapeutic target for pancreatic cancer","volume":"8","author":"Grell","year":"2022","journal-title":"Heliyon"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118657_bib47","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.bbapap.2014.06.019","article-title":"Structural characteristics of the nonallosteric human cytosolic malic enzyme","volume":"1844","author":"Hsieh","year":"2014","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib48","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1110\/ps.38002","article-title":"Structural studies of the pigeon cytosolic NADP + \u2010dependent malic enzyme","volume":"11","author":"Yang","year":"2002","journal-title":"Protein Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118657_bib50","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0969-2126(99)80115-4","article-title":"Crystal structure of human mitochondrial NAD(P)+-dependent malic enzyme: a new class of oxidative decarboxylases","volume":"7","author":"Xu","year":"1999","journal-title":"Structure"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118657_bib51","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0969-2126(03)00168-0","article-title":"Crystal structures of substrate complexes of malic enzyme and insights into the catalytic mechanism","volume":"11","author":"Tao","year":"2003","journal-title":"Structure"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118657_bib52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/0929867324666171006165942","article-title":"Sunitinib in the treatment of thyroid cancer","volume":"26","author":"Ferrari","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"43","key":"10.1016\/j.ejmech.2026.118657_bib53","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v21.i43.12234","article-title":"Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer","volume":"21","author":"Fujita","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib54","first-page":"93","article-title":"Literature review and practical aspects on the management of oxaliplatin-associated toxicity","volume":"11","author":"Hoff","year":"2012","journal-title":"Clin. Colorectal Cancer"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118657_bib55","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bjc.6602793","article-title":"Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII","volume":"93","author":"Pedersen","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118657_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113218","article-title":"FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: synthesis and clinical application","volume":"214","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118657_bib57","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1016\/j.bmcl.2006.04.080","article-title":"Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase","volume":"16","author":"Wang","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118657_bib58","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies leading to the identification of ZD1839 (iressaTM): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer","volume":"11","author":"Barker","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118657_bib59","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva\u00ae) tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11523-013-0258-9","article-title":"Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)","volume":"8","author":"Kobayashi","year":"2013","journal-title":"Targeted Oncol."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118657_bib61","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2174\/138955752203220202164839","article-title":"The Most recent discoveries in heterocyclic nanoformulations for targeted anticancer therapy","volume":"22","author":"Bhattacharya","year":"2022","journal-title":"Mini Rev. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13065-019-0579-6","article-title":"Benzimidazole scaffolds as promising antiproliferative agents: a review","volume":"13","author":"Tahlan","year":"2019","journal-title":"BMC Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2026.118657_bib63","doi-asserted-by":"crossref","first-page":"11808","DOI":"10.1039\/D2RA00927G","article-title":"Recent advancements in the multicomponent synthesis of heterocycles integrated with a pyrano[2,3- d ]pyrimidine core","volume":"12","author":"El-Khateeb","year":"2022","journal-title":"RSC Adv."},{"issue":"7810","key":"10.1016\/j.ejmech.2026.118657_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41586-020-2330-9","article-title":"Selective prebiotic formation of RNA pyrimidine and DNA purine nucleosides","volume":"582","author":"Xu","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10637-019-00762-y","article-title":"Discovery of a pyrimidine compound endowed with antitumor activity","volume":"38","author":"Taglieri","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2026.118657_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104480","article-title":"Synthesis, biological activity and POM\/DFT\/docking analyses of annulated pyrano[2,3-d]pyrimidine derivatives: identification of antibacterial and antitumor pharmacophore sites","volume":"106","author":"Bhat","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118657_bib67","doi-asserted-by":"crossref","first-page":"8978","DOI":"10.1080\/10406638.2022.2157453","article-title":"An efficient and green synthesis of new 6-Iodo- Pyrano[2,3-d] Pyrimidine-4-Ones via a one-pot four-component reaction followed by iodocyclization in water","volume":"43","author":"Rezaeifard","year":"2023","journal-title":"Polycycl. Aromat. Compd."},{"key":"10.1016\/j.ejmech.2026.118657_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105186","article-title":"Design, synthesis, molecular docking and in silico ADMET profile of pyrano[2,3-d]pyrimidine derivatives as antimicrobial and anticancer agents","volume":"115","author":"Abd El-Sattar","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118657_bib69","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/cmdc.202000378","article-title":"Recent development of pyrimidine\u2010containing antimicrobial agents","volume":"15","author":"Zhuang","year":"2020","journal-title":"ChemMedChem"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118657_bib70","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1007\/s00044-011-9915-7","article-title":"Synthesis, antimicrobial, and antioxidant activities of some new indole analogues containing pyrimidine and fused pyrimidine systems","volume":"21","author":"Raghunath","year":"2012","journal-title":"Med. Chem. Res."},{"issue":"43","key":"10.1016\/j.ejmech.2026.118657_bib71","doi-asserted-by":"crossref","first-page":"11021","DOI":"10.1002\/chem.202101363","article-title":"Enantioselective cross\u2010couplings between halide derivatives and organometallics by using iron and cobalt catalysts: formation of C\u2212C bonds","volume":"27","author":"Shu","year":"2021","journal-title":"Chem. Eur J."},{"issue":"2\u20133","key":"10.1016\/j.ejmech.2026.118657_bib72","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/adsc.201300776","article-title":"Chemoselective carbon\u2010carbon cross\u2010coupling via palladium\u2010catalyzed copper\u2010mediated CS Cleavcge of Disuldides","volume":"356","author":"Quan","year":"2014","journal-title":"Adv. Synth. Catal."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118657_bib73","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2174\/1871520622666220701113204","article-title":"An appraisal on synthetic and medicinal aspects of fused pyrimidines as anti neoplastic agents","volume":"23","author":"Rani","year":"2023","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"Jan","key":"10.1016\/j.ejmech.2026.118657_bib74","article-title":"Novel anticancer fused pyrazole derivatives as EGFR and VEGFR-2 dual TK inhibitors","volume":"7","author":"Saleh","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.118657_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113523","article-title":"Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy","volume":"221","author":"Ayati","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118657_bib76","doi-asserted-by":"crossref","first-page":"321","DOI":"10.7124\/bc.000A0F","article-title":"Anticancer activity evaluation of thieno[3,2-e][1,2,3]triazolo[1,5-a]pyrimidines and thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidine derivatives","volume":"35","author":"Shyyka","year":"2019","journal-title":"Biopolym. Cell"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118657_bib77","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1158\/0008-5472.CAN-17-3155","article-title":"ME1 regulates NADPH homeostasis to promote gastric cancer growth and metastasis","volume":"78","author":"Lu","year":"2018","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118657_bib78","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s13402-023-00812-x","article-title":"Targeting human mitochondrial NAD(P)+-dependent malic enzyme (ME2) impairs energy metabolism and redox state and exhibits antileukemic activity in acute myeloid leukemia","volume":"46","author":"Chen","year":"2023","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ejmech.2026.118657_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103273","article-title":"Malic enzymes in cancer: regulatory mechanisms, functions, and therapeutic implications","volume":"75","author":"Wang","year":"2024","journal-title":"Redox Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118657_bib80","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1038\/oncsis.2017.34","article-title":"Inhibition of malic enzyme 1 disrupts cellular metabolism and leads to vulnerability in cancer cells in glucose-restricted conditions","volume":"6","author":"Murai","year":"2017","journal-title":"Oncogenesis"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118657_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12761","article-title":"Ferroptosis: final destination for cancer?","volume":"53","author":"Ye","year":"2020","journal-title":"Cell Prolif."},{"issue":"Jun","key":"10.1016\/j.ejmech.2026.118657_bib82","article-title":"A promising future of ferroptosis in tumor therapy","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118657_bib83","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tips.2023.06.005","article-title":"Ferroptosis of immune cells in the tumor microenvironment","volume":"44","author":"Kim","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118657_bib84","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular senescence: defining a path forward","volume":"179","author":"Gorgoulis","year":"2019","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118657_bib85","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1134\/S1068162025600886","article-title":"A review on the synthesis and biological significance of oxadiazole (OXD) derivatives: sustainable green approaches and applications","volume":"51","author":"Shrivastava","year":"2025","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118657_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106754","article-title":"Development of novel pyrimidine nucleoside analogs as potential anticancer agents: synthesis, characterization, and In-vitro evaluation against pancreatic cancer","volume":"196","author":"Frimpong","year":"2024","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118657_bib87","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/molecules13081551","article-title":"5-Fluorouracil: Mechanisms of resistance and reversal strategies","volume":"13","author":"Zhang","year":"2008","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118657_bib88","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MPA.0000000000000323","article-title":"Pancreatic cancer disparities in African Americans","volume":"44","author":"Khawja","year":"2015","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118657_bib89","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/ph18050696","article-title":"Design, synthesis, anticancer evaluation and molecular docking of pyrimidine, Pyrido[4,3-d]pyrimidine and 5,6,7,8-Tetrahydropyrido[3,4-d]pyrimidine derivatives as novel KRAS-G12D inhibitors and PROTACs","volume":"18","author":"Yang","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.118657_bib90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/apc-24-21","article-title":"Synthesis and evaluation of novel pyrimidine derivative targeting pancreatic adenocarcinoma","volume":"7","author":"Panduranga Mudgal","year":"2024","journal-title":"Ann. Pancreat. Cancer"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118657_bib91","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00432-016-2178-4","article-title":"Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification","volume":"142","author":"Bhaw-Luximon","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118657_bib92","doi-asserted-by":"crossref","first-page":"djw275","DOI":"10.1093\/jnci\/djw275","article-title":"Influence of statins and cholesterol on mortality among patients with pancreatic cancer","volume":"109","author":"Huang","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib93","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s13238-020-00760-4","article-title":"Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation","volume":"12","author":"Wang","year":"2021","journal-title":"Protein Cell"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118657_bib94","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1021\/jacs.0c00650","article-title":"Metformin-Induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy","volume":"142","author":"Han","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib95","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/0008-5472.CAN-19-3415","article-title":"Statins limit coenzyme Q synthesis and metabolically synergize with MEK inhibition in pancreatic tumors","volume":"80","author":"Cordes","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-023-02671-8","article-title":"Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo\/YAP1\/c-Jun axis","volume":"42","author":"Zhou","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib97","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","article-title":"A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors","volume":"71","author":"Raez","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118657_bib98","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jhet.3830","article-title":"Synthesis of Pyrano[2,3\u2010 d ]pyrimidine\u20102,4\u2010diones and Pyridino[2,3\u2010 d ]pyrimidine\u20102,4,6,8\u2010tetraones: evaluation Antitumor activity","volume":"57","author":"Haggam","year":"2020","journal-title":"J. Heterocycl. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118657_bib99","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s13738-019-01633-2","article-title":"Straightforward multicomponent synthesis of pyrano[2,3-d]pyrimidine-2,4,7-triones in \u03b2-cyclodextrin cavity and evaluation of their anticancer activity","volume":"16","author":"Bhosle","year":"2019","journal-title":"J. Iran. Chem. Soc."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118657_bib100","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ardp.200700005","article-title":"Synthesis of Pyrazolo[4\u2032,3\u2032:5,6]pyrano[2,3\u2010 d ]pyrimidine derivatives for antiviral evaluation","volume":"340","author":"Shamroukh","year":"2007","journal-title":"Arch. Pharm. (Weinheim)"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118657_bib101","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00044-014-1313-5","article-title":"Synthesis, characterization and in vitro antimicrobial evaluation of some novel hydrazone derivatives bearing pyrimidinyl and pyrazolyl moieties as a promising heterocycles","volume":"24","author":"Kamal","year":"2015","journal-title":"Med. Chem. Res."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118657_bib110","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41419-024-06930-0","article-title":"Emerging mechanisms and promising approaches in pancreatic cancer metabolism","volume":"15","author":"Wu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118657_bib102","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00109-011-0785-8","article-title":"Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo","volume":"89","author":"Zachar","year":"2011","journal-title":"J. Mol. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118657_bib103","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S1470-2045(17)30314-5","article-title":"Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial","volume":"18","author":"Alistar","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118657_bib104","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/0008-5472.CAN-23-3954","article-title":"DON of hope: starving pancreatic cancer by glutamine antagonism","volume":"84","author":"Pillai","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118657_bib105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2019.10.020","article-title":"Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: an open-label, randomized Phase IIb trial","volume":"124","author":"Hammel","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118657_bib106","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyac174","article-title":"Epacadostat plus pembrolizumab and chemotherapy for advanced solid tumors: results from the phase I\/II ECHO-207\/KEYNOTE-723 study","volume":"27","author":"Powderly","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118657_bib107","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40170-015-0137-1","article-title":"Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by \u00df-lapachone","volume":"3","author":"Chakrabarti","year":"2015","journal-title":"Cancer Metabol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118657_bib108","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1039\/D0RA10657G","article-title":"Research developments in the syntheses, anti-inflammatory activities and structure\u2013activity relationships of pyrimidines","volume":"11","author":"ur Rashid","year":"2021","journal-title":"RSC Adv."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118657_bib109","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.ejmech.2010.02.048","article-title":"Analgesic, anti-pyretic and DNA cleavage studies of novel pyrimidine derivatives of coumarin moiety","volume":"45","author":"Keri","year":"2010","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:39:32Z","timestamp":1775482772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426001029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":110,"alternative-id":["S0223523426001029"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118657","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in pyrimidine-like heterocyclic scaffolds: Innovative synthetic method for malic enzyme inhibition in pancreatic ductal adenocarcinoma (PDAC) - A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118657"}}